Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$5.4 million.

  • Vivos Therapeutics' Consolidated Net Income fell 10642.2% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.2 million, marking a year-over-year decrease of 3608.75%. This contributed to the annual value of -$11.2 million for FY2024, which is 1784.82% up from last year.
  • As of Q3 2025, Vivos Therapeutics' Consolidated Net Income stood at -$5.4 million, which was down 10642.2% from -$5.0 million recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' Consolidated Net Income peaked at -$1.7 million during Q1 2023, and registered a low of -$7.4 million during Q4 2021.
  • In the last 5 years, Vivos Therapeutics' Consolidated Net Income had a median value of -$4.3 million in 2023 and averaged -$4.4 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 19729.47% in 2021, then soared by 6805.48% in 2023.
  • Vivos Therapeutics' Consolidated Net Income (Quarter) stood at -$7.4 million in 2021, then grew by 17.85% to -$6.1 million in 2022, then grew by 29.35% to -$4.3 million in 2023, then surged by 32.94% to -$2.9 million in 2024, then plummeted by 87.18% to -$5.4 million in 2025.
  • Its last three reported values are -$5.4 million in Q3 2025, -$5.0 million for Q2 2025, and -$3.9 million during Q1 2025.